XPhyto Announces OTCQB Venture Market Listing

ID: 1560123
recent pressrelease next pressrelease

(businesspress24) - Vancouver, Canada (August 14, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (XPhyto or the Company), a next generation bioscience company, is pleased to announce that its common shares are now trading on the OTCQB Venture Market ("OTCQB Venture") under the stock symbol XPHYF.


The OTCQB Venture is the premiere marketplace for early stage and developing U.S. and international companies. Participating companies must be current in their reporting and undergo an annual verification and management certification process. Investors can find real-time quote and market information at https://www.otcmarkets.com/stock/XPHYF/overview.

XPhyto is also pleased to announce that its common shares are eligible for electronic settlement and transfer in the United States by The Depository Trust Company ("DTC").

XPhytos common shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol XPHY as well as the Frankfurt Stock Exchange under the symbol 4XT.

About XPhyto Therapeutics Corp.

XPhyto is a diversified bioscience company with strategic assets and investments in the field of next generation drug delivery and rapid pathogen screening systems, as well as medical cannabis opportunities focused on European markets. Through its 100% owned subsidiaries and exclusive collaboration agreements, XPhyto is pursuing clinical programs for the transdermal and dissolvable oral delivery of conventional and cannabis based narcotics for neurological applications, as well as rapid dissolvable oral biosensor and lateral flow assay-based screening tests for dental health applications and high-risk pandemic threats such as SARS-COV-2 (COVID-19), H1N1 (swine flu) and H5N1 (avian flu). XPhyto has two exclusive cannabis collaborations with the Technical University of Munich, and two exclusive 5-year engagements with the University of Alberta, Faculty of Pharmacy and Pharmaceutical Sciences for cannabis extraction, isolation, formulation, and analytical testing.



ON BEHALF OF THE BOARD
Hugh Rogers
Hugh Rogers, CEO and Director

Investor Inquiries:
Mr. Knox Henderson
Tel: 604-551-2360
info(at)xphyto.com
www.xphyto.com


Forward looking statements

This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as develop, "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company''s goal of building a successful diagnostic, drug delivery, and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not succeed in developing a commercial product; that the sale of products may not be a viable business; that the Company may be unable to scale its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; currency risks; competition; international risks; and other risks beyond the Company''s control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.



More information:
http://



Keywords (optional):



Company information / Profile:

PressRelease by

Requests:

XPhyto ist ein wissenschaftlich ausgerichtetes Cannabisunternehmen, das analytische Test-, Verarbeitungs- und Formulierungskapazitäten in Kanada entwickelt, während sich das Unternehmen in Deutschland auf Forschung, Anbau, Extraktion, Import, Vertrieb und Herstellung konzentriert.



PressContact / Agency:



published by: irw
print pressrelease  send to a friend  

Date: 08/14/2020 - 09:07
Language: English
News-ID 1560123
Character count: 4375
Kontakt-Informationen:
Firma: XPhyto Therapeutics Corp.
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Wien
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 353

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 63


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.